Skip to content
Biotechnology, Medical Health Aged Care

Blood test to detect dementia: expert available for comment

Neuroscience Research Australia < 1 mins read
Prof Matthew Kiernan AM is a distinguished clinical academic and scientist renowned for his expertise in neurodegenerative diseases, particularly motor neuron disease (MND) and frontotemporal dementia (FTD)

Professor Matthew Kiernan AM CEO at Neuroscience Research Australia is available to provide expert comment on the development of an early blood test to predict dementia, as reported by the Guardian today based on research published in nature aging

Professor Kiernan AM is an expert in neurodegenerative diseases, particularly motor neuron disease (MND) and frontotemporal dementia (FTD). He is a clinician scientist based at NeuRA. 

 


Contact details:

Contact Michelle Smith OR Beatrix Kates

Senior Communications & PR Officer

0452 140 477

michelle.smith@neura.edu.au

b.kates@neura.edu.au

 

Media

More from this category

  • Medical Health Aged Care
  • 24/02/2024
  • 07:07
CGFNS International

CGFNS International Unveils New Think Tank to Advance Health Workforce Development Scholarship and Solutions Worldwide?

PHILADELPHIA, PA / ACCESSWIRE / February 23, 2024 / CGFNS International announced today it has established a Global Health Workforce Development Institute. The new think tank will conduct original research and leverage knowledge developed by CGFNS over its half-century of providing credentialing services -- as well as its vast experience with workforce mobility issues -- to advance scientific knowledge about the evolution of health workforce roles and the development of credentialing and certification programs and policies.CGFNS International A long-term objective of the Institute will be to create rigorous global certification programs that streamline the assessment and recognition of practice competency.…

  • Medical Health Aged Care
  • 24/02/2024
  • 02:52
Tilray Brands, Inc.

Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany

New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanGCOLOGNE, Germany and NEUMÜNSTER, Germany, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that its medical cannabis division, Tilray Medical, the global leader in medical cannabis, enthusiastically welcomes the opening of the German medical cannabis market and the positive paradigm shift in German drug policy. Today’s landmark passage of the German Medical Cannabis Act represents a significant step forward and puts public health in the spotlight…

  • Medical Health Aged Care
  • 23/02/2024
  • 17:25
Royal Australian College of GPs

RACGP appoints new CEO

Georgina van de Water has been appointed as the new Chief Executive Officer of the Royal Australian College of GPs (RACGP). Ms van de…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.